anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention discloses a stocking sole for treating the verruca plantaris. The stocking sole comprises a stocking sole body (1). A binding belt (2) is arranged on the stocking sole body (1). The stocking sole is characterized in that a pit concave block (5) which enables a user to conveniently walk after containing medicine and prevents medicine from being extruded out is arranged on the stocking sole body (1), a concave thin film (8) for preventing liquid medicine from overflowing is put on the pit concave block (5), and a medicine fluff column for treating the verruca plantaris is built in the pit concave block (5). In order to treat the verruca plantaris, according to the preparation process, adopted medicine including fresh centella asiatica and raw tung oil and the medicine fluff column obtained through the preparation method are put on the pit concave block (5) and used for being attached below themetatarsophalangeal joints and around wart affected toes, and then the treatment aim is achieved. The stocking sole has the advantages of being reliable in treatment effect, low in manufacturing cost and free of pain during operation and overcomes the defects that medicine is extruded out and the user can not conveniently walk when the medicine is laid below a foot sole.
OBJECTIVE: This study aims to explore the appropriate surgical treatment method for acute intestinal obstruction caused by gastrointestinal foreign bodies in children through a comparison of clinical characteristics in patients treated via laparoscopically assisted approach and open surgery.
METHODS: This study retrospectively analyzed 12 children with acute intestinal obstruction caused by gastrointestinal foreign bodies treated at Shanghai Children's Hospital and Huzhou Maternity and Child Care Hospital from June 2019 to June 2024. Basic information, treatment methods, and prognoses of the patients were collected. General data, operation time, postoperative fasting time, postoperative hospital stay, and intraoperative and postoperative complications were compared between the two groups. Categorical data were compared using Fisher's exact test. Normally distributed continuous data were expressed as mean ± standard deviation and analyzed using an independent samples t-test; non-normally distributed data were expressed as M (P25, P75) and analyzed using the non-parametric Mann-Whitney U test.
RESULTS: Six cases underwent laparoscopic transumbilical extended incision, successfully extracting the intestines and removing the foreign bodies without converting to open surgery. Compared to Six cases undergoing traditional open surgery during the same period, the postoperative fasting time and postoperative hospital stay in the laparoscopic group were 4 (5 ± 3.65) days and 5.5 (5 ± 7.5) days, respectively, while in the traditional open surgery group, they were 5 (4.25 ± 6) days and 6 (5 ± 8.6) days, respectively; the differences were statistically significant (P < 0.05). The laparoscopic group had significantly shorter operation time and faster postoperative recovery. The acceptance of the laparoscopically assisted approach by the families was significantly higher than that of the open surgery treatment.
CONCLUSION: The method of extracting obstructed intestines and removing foreign bodies via laparoscopic-assisted transumbilical extended incision has advantages over open surgery for treating acute intestinal obstruction caused by gastrointestinal foreign bodies, such as shortening hospital stay and operation time. However, for children with secondary gastrointestinal perforation caused by magnetic foreign bodies, open surgery, due to its broader exploration scope, is more advantageous for detecting occult perforations.
Methotrexate (MTX) was given as variable dosing regimen of 7.5 mg-15 mg weekly. Intravenous (IV) Placebo Solution, given in the same mode of administration as the canakinumab solution.
Pregnancy Category C.

No treatment-related malformations were observed when lopinavir in combination with ritonavir was administered to pregnant rats or rabbits. Embryonic and fetal developmental toxicities (early resorption, decreased fetal viability, decreased fetal body weight, increased incidence of skeletal variations and skeletal ossification delays) occurred in rats at a maternally toxic dosage. Based on AUC measurements, the drug exposures in rats at the toxic doses were approximately 0.7-fold for lopinavir and 1.8-fold for ritonavir for males and females that of the exposures in humans at the recommended therapeutic dose (400/100 mg twice daily). In a peri- and postnatal study in rats, a developmental toxicity (a decrease in survival in pups between birth and postnatal Day 21) occurred.

No embryonic and fetal developmental toxicities were observed in rabbits at a maternally toxic dosage. Based on AUC measurements, the drug exposures in rabbits at the toxic doses were approximately 0.6-fold for lopinavir and 1.0-fold for ritonavir that of the exposures in humans at the recommended therapeutic dose (400/100 mg twice daily). There are, however, no adequate and well-controlled studies in pregnant women. KALETRA should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Antiretroviral Pregnancy Registry: To monitor maternal-fetal outcomes of pregnant women exposed to KALETRA, an Antiretroviral Pregnancy Registry has been established. Physicians are encouraged to register patients by calling 1-800-258-4263.
Participants were randomly assigned to ingest in a double-blind manner caplets containing a commercially available glucosamine/chondroitin (GC) dietary supplement (Curves Joint and Connective Support™, Curves International, Waco, TX) or a suitable placebo (P). The GC supplement provided a total of 1,500 mg/d of glucosamine, 1,200 mg/d of chondroitin sulfate, 120 mg/d of niacin, 120 mg/d of sodium, 45 mg/d of zinc, 900 mg/d MSM, 300 mg/d of boswellia serrata extract, 180 mg/d of white willow bark extract, and 15 mg/d of rutin powder. Participants ingested three caplets in the morning and the remaining three caplets in the evening 30-minutes before a meal for 14-weeks.
PURPOSE: Corneal infections are a leading cause of visual impairment and blindness worldwide. Here we applied high-resolution transcriptomic profiling to assess the general and pathogen-specific molecular and cellular mechanisms during human corneal infection.
METHODS: Clinical diagnoses of herpes simplex virus (HSV) (n=5) and bacterial/fungal (n=5) keratitis were confirmed by histology. Healthy corneas (n=7) and keratoconus (n=4) samples served as controls. Formalin-fixed, paraffin-embedded (FFPE) human corneal specimens were analyzed using the 3' RNA sequencing method Massive Analysis of cDNA Ends (MACE RNA-seq). The cellular host response was investigated using comprehensive bioinformatic deconvolution (xCell and CYBERSORTx) analyses and by integration with published single cell RNA-seq data of the human cornea.
RESULTS: Our analysis identified 216 and 561 genes, that were specifically overexpressed in viral or bacterial/fungal keratitis, respectively, and allowed to distinguish the two etiologies. The virus-specific host response was driven by adaptive immunity and associated molecular signaling pathways, whereas the bacterial/fungal-specific host response mainly involved innate immunity signaling pathways and cell types. We identified several genes and pathways involved in the host response to infectious keratitis, including CXCL9, CXCR3, and MMP9 for viral, and S100A8/A9, MMP9, and the IL17 pathway for bacterial/fungal keratitis.
CONCLUSIONS: High-resolution molecular profiling provides new insights into the human corneal host response to viral and bacterial/fungal infection. Pathogen-specific molecular profiles may provide the foundation for novel diagnostic biomarker and therapeutic approaches that target inflammation-induced damage to corneal host cells with the goal to improve the outcome of infectious keratitis.
The most common and serious complication among hospitalized and critically ill patients is sepsis-associated acute kidney damage (S-AKI), which raises the risk of comorbidities and is linked to a high mortality rate. Cholinergic anti-inflammatory pathway (CAP), an anti-inflammatory pathway mediated by the vagus nerve, acetylcholine, and α7 nicotinic acetylcholine receptors (α7nAChRs), offers new perspectives for the treatment of S-AKI. In this study, we investigated the role of CAP and α7nAChR in kidney injury by employing an LPS-induced septic kidney injury mouse model and GTS-21 intervention. C57BL/6 mice were injected with LPS, with or without GTS-21, in different subgroups. Kidney function was assessed by plasma creatinine, histology, and markers of kidney injury 24 h after intervention. The results demonstrated that GTS-21 could inhibit the systemic inflammatory response and directly protect the tubular cell injury from LPS. To explore the novel gene involved in this response, RNA sequencing of the renal proximal tubular epithelial cell (HK-2), pretreated with LPS and GTS-21, was conducted. The results indicate that GTS-21 administration reduces LPS-induced cytokines and chemokines secretion by HK-2, including CCL20, a potent chemokine attracting monocytes/macrophages. Furthermore, a macrophage transmigration assay revealed that GTS-21 inhibits macrophage transmigration by downregulating the expression of CCL20 in HK-2 cells. In conclusion, GTS-21, as an α7nAChR agonist, emerges as a noteworthy and versatile treatment for S-AKI. Its dual function of directly protecting renal tubular cells and regulating inflammatory responses represents a major advancement in the treatment of sepsis-induced AKI. This finding might pave the way for novel approaches to improving patient outcomes and reducing death rates in sepsis-related complications.
PURPOSE:To provide a granular fungicide handy to carry, storable for a long period without losing the activity, suitable for the preparatory washing, and composed of granular acidic polysaccharide capsules containing an aqueous solution of benzalkonium chloride as a core and made water-insoluble by benzalkonium chloride. CONSTITUTION:Granules composed of an acidic polysaccharide insolubilized by benzalkonium chloride as the outer layer and an aqueous solution of benzalkonium chloride as the core (preferably the diameter of the granule is 0.2-5mm.) are prepared by contacting 1pt. of a 0.1-40% fluid aqueous solution of a water- soluble acidic polysaccharide with 0.1-5pts. of an aqueous solution containing >=0.01% of benzalkonium chloride under agitation of one or both of the components. The fungicidal effect of benzalkonium chloride can be exhibited by collapsing the capsule with pressure in use. The acidic polysacchride is e.g. carrageenan, agar, sodium alginate, gum arabic, CMC-Na, carboxymethylguar sodium salt, etc.
The data described below reflect exposure to Imiquimod Cream or vehicle in 479 subjects enrolled in two double-blind, vehicle-controlled trials. Subjects applied up to two packets of Imiquimod Cream or vehicle daily to the skin of the affected area (either entire face or balding scalp) for two 2-week treatment cycles separated by a 2-week no-treatment period.

Local skin reactions were recorded as adverse reactions only if they extended beyond the treatment area, if they required any medical intervention, or they resulted in patient discontinuation from the study. The incidence and severity of selected local skin reactions are shown in Table 2.

Overall, in the clinical trials, 11% (17/160) of subjects in the Imiquimod Cream, 3.75% arm, 7% (11/160) of subjects in the Imiquimod Cream, 2.5% arm, and 0% in the vehicle cream arm required rest periods due to adverse local skin reactions.

Other adverse reactions observed in subjects treated with Imiquimod Cream include: application site bleeding, application site swelling, chills, dermatitis, herpes zoster, insomnia, lethargy, myalgia, pancytopenia, pruritus, squamous cell carcinoma, and vomiting.
OBJECTIVE: To identify the risk factors for relapse of idiopathic inflammatory myopathies (IIMs).
METHODS: Patients who were newly diagnosed with IIMs and underwent muscle biopsy between 2000 and 2017 at Asan Medical Center were retrospectively reviewed. The relapse of IIMs was defined as the recurrence of muscle or cutaneous manifestations with a ≥50% increase in glucocorticoid dosage after reaching the low-dose glucocorticoid phase with clinically significant improvement. The factors associated with the relapse of IIMs were investigated by Cox proportional hazards analysis.
RESULTS: Of 105 patients with IIMs, relapse was observed in 65 patients (62%). The titer of antinuclear antibody (ANA) was higher in the relapse group than in the non-relapse group (P = 0.033). Multivariable analysis showed that the relapse of IIMs was significantly associated with histopathologic features consistent with IIMs (hazard ratio [HR], 1.69; 95% confidence interval [CI], 1.01-2.83, P = 0.045) and the use of immunosuppressants before relapse (HR, 0.50; 95% CI, 0.29-0.86, P = 0.013). Doubling of ANA titer was also associated with relapse, albeit without statistical significance (HR, 1.13; 95% CI, 1.00-1.27, P = 0.052).
CONCLUSION: In patients with IIMs, the use of immunosuppressants had a significant negative association with relapse. Administering immunosuppressants from the early period during the initial glucocorticoid tapering phase may be useful in reducing the risk of relapse in patients with IIMs. Key Points • Since idiopathic inflammatory myopathies (IIMs) have a low prevalence, it is poorly understood which factors are associated with the relapse of IIMs. • In this study, about two-thirds of 105 patients with IIMs experienced a relapse of IIMs. • The risk of relapse in patients with IIMs was negatively associated with the use of immunosuppressants during glucocorticoid tapering and low-dose glucocorticoid phase. • Even in less severe cases, the use of immunosuppressants might be a good option for the management of IIMs.
Transfusion-transmitted hepatitis E virus (HEV) infection is an increasing concern in many countries. We investigated the detection rate of HEV viremia in blood donors in Russia. A total of 20,405 regular repetitive voluntary non-renumerated blood donors from two regions (Moscow and Belgorod) were screened for HEV RNA using the cobas® HEV test in mini-pools of six plasma samples. Samples from each reactive pool were tested individually. The average HEV RNA prevalence was 0.024% (95% CI: 0.01-0.05%), or 1 case per 4081 donations. No statistically significant differences in HEV RNA prevalence were observed between the two study regions. The PCR threshold cycle (Ct) values ranged from 25.0 to 40.5 in reactive pools, and from 20.9 to 41.4 in reactive plasma samples when tested individually. The HEV viremic donors had different antibody patterns. Two donor samples were reactive for both anti-HEV IgM and IgG antibodies, one sample was reactive for anti-HEV IgM and negative for anti-HEV IgG, and two samples were seronegative. At follow-up testing 6 months later, on average, four donors available for follow-up had become negative for HEV RNA and positive for anti-HEV IgG. The HEV ORF2 sequence belonging to HEV-3 sub-genotype 3a was obtained from one donor sample. The sequencing failed in the other four samples from viremic donors, presumably due to the low viral load. In conclusion, the HEV RNA detection rate in blood donors in Russia corresponds with data from other European countries, including those that implemented universal donor HEV screening. These data support the implementation of HEV RNA donor screening to reduce the risk of transfusion-transmitted HEV infection in Russia.
Functional magnetic resonance imagery allows identification of correlations during rest between remote brain areas (functional connectivity) through their highly correlated low-frequency spontaneous fluctuations. This technique is interesting because it is atraumatic, takes place in resting condition, without administration of substances. Only one study of connectivity with functional magnetic resonance imagery in resting state, in headache-free period of migraine, has shown differences in the connection of the periaqueductal gray matter to the pain matrix in migraineurs and controls. Our region of interest is the hypothalamus because our group demonstrated activation in this area during migraine attacks and we hypothesised that the hypothalamus could trigger migraine attacks. We want to compare 2 groups of migraineurs. The first group is composed of chronic migraineurs with \>15 days with headache per month, compared to the 2nd group composed of age- and gender-matched episodic migraineurs with \< 4 days of migraine per month, without prophylactic treatment. Our purpose is to study the connectivity of the hypothalamus to midbrain and pons areas activated in previous studies using positon emission tomography (PET) in spontaneous migraine attacks. The connectivity of the hypothalamus with the trigeminal-cervical complex, conveying the pain from cranial vasculature and dura-mater playing a major role in migraine attack, has never been studied before, mainly for anatomical reasons. Our secondary purpose is to study the connectivity of the hypothalamus with the pain matrix and the possible correlations with depression, allodynia and attack treatment overuse.

The primary outcome is the connectivity index of the hypothalamus to the midbrain and pons area known to be activated in migraine attacks and the trigeminal-cervical complex The secondary outcome is the connectivity index of the hypothalamus with the pain matrix (thalamus, sensitive-motor cortex, cingular cortex) This study is a comparative monocentric pathophysiological study of patients with migraine.
Healthy volunteers will receive a baseline MRI. On the night before and day of testing, subjects will receive two doses of calcitriol (3.0mcg total), followed by PHNO injection and PET Scan #1. After PET Scan #1, subjects will receive a Dexedrine dose, followed by PHNO injection and PET Scan #2. A minimum of six days later, subjects will receive two doses of placebo for the night before and day of testing, followed by a third PHNO injection and PET scan #3. After PET scan #3, subjects will receive another Dexedrine dose, followed by PHNO injection and PET scan #4.
Male subjects were recruited for the study based on the following criteria: age between 18 and 50, body mass index normal or obese, non-smokers, non-alcoholic, and do not take medications. Subjects did an acceptability test on custard and completed a screening questionnaire. Around 30 subjects (15 with a normal BMI and 15 obese) continued the study. Subjects were randomly assigned to one of two meals. Each of the two meals was ingested after a 3-day adaptation period. The meals had similar macronutrient composition and provided energy equivalent to 30% of the subjects' resting energy expenditure. At each test day, fasting blood samples were withdrawn by a registered nurse under sterile conditions. This procedure was followed by ingestion of one of the two meals within a period of 10-15 minutes. Blood samples of 5 ml were collected at fasting and after ingestion of meals at 15, 30, 60, 120, 180 and 240 minutes. At the end, subjects were given ad lib access to cheese pizza to assess energy intake after the custard preload. Blood analysis for GLP-1, ghrelin, insulin and glucose levels were performed.
The invention belongs to the technical fields of biological medicine and molecular biology, and in particular relates to a bone targeting co-delivery bortezomib and pomalidomide nanocomposite, and a preparation method and application thereof. The bone-targeting acid-sensitive nano micelle is successfully prepared. After intravenous injection, the micelles remain stable in the blood circulation and target the bone marrow microenvironment by chelation between alendronic acid on the nanoparticle surface and calcium phosphate in the bone matrix. In the acidic environment of tumor, the nano micelle is pH sensitive degraded to release free drugs bortezomib and pomalidomide. Wherein bortezomib acts on the 26S proteasome, disrupting misfolded proteins, leading to apoptosis of tumor cells; in addition, pomalidomide inhibits inflammatory factors, blocks angiogenesis, mobilizes the immune system, and synergistically inhibits tumor growth. Meanwhile, the use of the micelle can obviously reduce the systemic toxic and side effects caused by the medicines, so that the micelle has excellent practical application value.
<P>PROBLEM TO BE SOLVED: To provide a new flavanone compound which exhibits a high anti-oxidizing action, its manufacturing method, and an antioxidant.  <P>SOLUTION: The flavanone compound has a structure represented by formula (1), formula (2) or formula (3). The flavanone compound can be obtained by using propolis including Macaranga tanarius Muell. Arg. of the origin plant as the raw material, and performing an extraction step of extracting an extract component containing the flavanone compound and then a separation step of separating the flavanone compound from the extract component. The flavanone compound having a structure represented by formula (3) can be obtained by using Macaranga tanarius Muell. Arg. as the raw material and performing the above extraction step and separation step. The antioxidant contains the above flavanone compound as an active ingredient.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
The invention relates to microspheres, more particularly to microspheres comprising a core, a functional layer and a solid oxide coating, wherein the functional layer forms an intermediate layer between the core and the solid oxide coating. The invention also relates to methods of making such microspheres. The microspheres may further comprise a priming layer, wherein the priming layer forms an intermediate layer between the solid oxide coating and the functional layer. The microspheres may further comprise an anchoring agent, wherein the functional layer is anchored to the core by binding to the anchoring agent. The functional layer comprises a magnetizable agent, a fluorescent agent, a coloured agent or a radioactive agent. Coupling agents such as silane and a germane are used.
Artemisia annua  and  A. afra  dichloromethane extracts contain bactericidal activity against  Mycobacterium tuberculosis  (Mtb) strain mc 2 6230 under natural infection stress conditions: carbon source metabolism (glycerol, dextrose, and cholesterol) and hypoxia. Significant bactericidal activity against Mtb was observed regardless of carbon source. Extracts from  A. afra  showed the highest bactericidal activity against Mtb for tested carbon sources, and  A. annua  bactericidal activity was greatest against Mtb in minimal media with glycerol.  A. annua  and  A. afra . extracts were bactericidal against Mtb under hypoxic conditions. Growth was halted and viability diminished several logs-fold under hypoxic conditions in the presence of each extract. Transcriptomic analysis revealed that  A. afra  exerts different effects on Mtb than artemisinin, indicative of phytochemicals in  A. afra  with unique modes of action. Biochemometric analysis of  A. afra  resulted in isolation of a methoxylated flavone (compound 1), with considerable activity against Mtb strain mc 2 6230.